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The mTOR pathway is an essential regulatory protein thatis involved in cell survival and management of stress
response, particularly related to nutrient deprivation. This
pathway is dysregulated in various malignancies, including
lung cancer. A number of agents that inhibit the mammalian
target of rapamycin (mTOR) pathway are in various stages of
development.
SUMMARY OF PRESENTATIONS
Temsirolimus
Temsirolimus, a rapamycin analog, has already been
approved for the treatment of patients with advanced renal
cell cancer. This agent has not been extensively studied in
lung cancer. Dr. Karen Reckamp discussed the results of the
City of Hope-UCLA phase I study of Temsirolimus in which
one patient with lung cancer had a partial response that lasted
more than 1 year. In the first line setting, a phase II clinical
trial of 55 patients noted a response rate of 8% and SD of
30%. In small cell lung cancer, CCI 779 was tested in the
maintenance setting and was not associated with improve-
ment in outcome. Ongoing/proposed studies include evalua-
tion in combination with radiation, carboplatin/paclitaxel, and
in the neoadjuvant settings.
Everolimus
Everolimus or RAD001, another novel mTOR inhibi-
tor, is being developed in lung cancer. A phase II study by
Papadimitrikapolou et al. evaluated RAD001 as monotherapy
of NSCLC in patients with disease progression following one
or two prior regimens. A total of 85 patients were enrolled to
the two-arm phase II study (prior chemotherapy alone, prior
chemotherapy, and EGFR inhibitor). The most common side
effects were mucositis, fatigue, and gastrointestinal toxicity.
An encouraging response rate was noted in 7% and 3% in the
two cohorts of patients, respectively. The median progres-
sion-free survival was 11.3 and 11.6 weeks for the two
cohorts. This study demonstrates the single agent activity of
RAD001 in advanced NSCLC. An exploratory immunohis-
tochemistry analysis suggested an adverse prognostic signif-
icance with AKT activation.
Preclinical studies have also demonstrated enhance-
ment of activity with the addition of RAD001 with chemo-
therapeutic agents. A number of clinical trials with combina-
tion regimens that include RAD001 have been initiated. It has
been suggested that the sequence of the combination may
play a major role in outcome. Phase I studies have now
documented the feasibility of administering RAD001 (5 mg
Qd or 30 mg Q week) in combination with carboplatin and
paclitaxel (n  26 patients). Neutropenia was the dose-
limiting toxicity with this regimen. When given in combina-
tion with pemetrexed, up to 5 mg per day and 50 mg per week
are tolerable. In small cell lung cancer, RAD001 was evalu-
ated in combination with the cisplatin-etoposide regimen.
Initial data suggest that the combination is associated with a
high degree of myelosuppression and might require the ad-
dition of prophylactic colony stimulating factors to improve
the safety of the regimen.
Johnson et al. are conducting a phase I/II study of
erlotinib and RAD001 in advanced NSCLC. The primary
endpoint of the phase I study was to evaluate the feasibility of
the combination with both the daily and weekly schedule of
RAD001. Patients who received one or two prior regimens
for advanced NSCLC were eligible. Ninety-two patients were
enrolled to the phase I study. The common toxicities were
rash, mucositis, and diarrhea. Both the 2.5 mg and 5 mg doses
of RAD001 were feasible with 150 mg of erlotinib. Ten of 72
patients had objective responses, with all responses noted in
the daily RAD001 cohort. The daily schedule at 5 mg was
chosen for further evaluation in an ongoing randomized phase
II study (erlotinib with or without RAD001).
Sirolimus
Sirolimus, the oldest mTOR inhibitor, has multiple mech-
anisms of action impacting tumor cell proliferation, angiogene-
sis, and regulation of T cells. Prolonged treatment with sirolimus
in preclinical models does not result in activation of mTOR. As
a single agent, sirolimus is likely to be active only in genetically
simple cancer models, such as in the chemoprevention setting.
Dennis et al. are planning a pilot prevention study with sirolimus
to evaluate changes in the bronchial epithelium. It has also been
suggested that certain germline events such as pTEN mutations
may lead to higher sensitivity to rapamycin. TSC2, which is
mutated in tuberous sclerosis, is modulated by rapamycin as
evidenced by regression of lymphangioleiomyomatosis in chil-
dren with tuberous sclerosis. Interestingly, prolonged disease
stabilization lasting 2 years were noted in a patient with
Cowden syndrome with rapamycin therapy. These observations
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have prompted a phase II study with the combination of rapa-
mycin and pemetrexed in neurofibromatosis.
AZD 6244
Another novel strategy that is being investigated in-
volves inhibition of the MEK protein. AZD 6244 is a novel
MEK inhibitor that exerts anticancer effect against a variety
of in vivo and in vitro cancer models. In phase I studies,
anticancer activity has been seen in melanoma and other
cancers (stable disease). In patients with advanced NSCLC,
monotherapy resulted in modest activity. Skin rash, diarrhea,
nausea, and emesis were the common toxicities. Based on
exciting preclinical data with the combination of AZD6244
with PI3 kinase inhibitors, which block mutant transgenic
mouse K-ras induced lung tumors, further studies are likely
to be pursued in the near future. An oral formulation of this
agent has been developed recently.
OXA 01 and OSI 027
Dr. Andrew Stephens reported on the preclinical devel-
opment OXA 01, a new agent that has recently entered
clinical evaluation that inhibits both mTORC1 and 2. Reduc-
tion of p4E-BP1 and other downstream signals are inhibited
with this agent in preclinical models. Anticancer activity has
been seen in a variety of cell lines including lung cancer. In
xenograft models, tumor regression in excess of 80% has
been noted. OSI 027 is a slightly modified molecule, which is
being tested in phase I studies. Three schedules are being
tested (weekly, 3 days on, 7 days off, and daily). Even at the
first-dose level of 10 mg four times per day in the clinic, the
time-above threshold concentrations were associated with
desired downstream effects. Inhibition of 4E-BP1 was noted
within 4 hours of drug administration on PBMCs.
Deferolimus
Deferolimus is another novel inhibitor of the mTOR
pathway. Dr. Rudin discussed the results of phase I studies
with both IV and oral formulations of this agent. The dose-
limiting toxicity was mucositis. A response rate of approxi-
mately 10% with responses in patients with sarcoma and
renal cell carcinoma has been noted. A randomized discon-
tinuation study is underway in patients with previously
treated NSCLC with a schedule of 40 mg PO four times per
day for 5 of 7 days every week. The study is restricted to
patients with K-ras mutation in tumor tissue. A total of 150
patients will be enrolled with progression-free survival as the
primary endpoint.
BEZ 235
Dr. Hackl discussed the clinical development of BEZ
235, a dual mTOR/pan-class PI3 kinase inhibitor. It has
demonstrated antiproliferative effects in a variety of tumor
models. Lethality was noted primarily in pathway-addicted
tumors, such as those with mutated PI3K or ErbB2 amplifi-
cation. A first-in-human phase I study has already been
initiated. Once the maximum tolerated dose (MTD) is
reached, an expansion arm with selected pathway-addicted
tumors will be undertaken. Of the 59 patients enrolled, no
DLT has been reported to date. Doses of up to 1100 mg four
times per day have been tolerated well so far. Toxicities
included grade 1 to 2 nausea, emesis, and diarrhea. No
long-term changes in glucose metabolism were noted. One
patient with NSCLC had stable disease for 4 months.
Dose-linear increase in BEZ 235 exposure (PK) was noted,
and the expected human MTD seems to be higher than that
projected MTD based on experiments in dogs. BEZ 235
reduced pS6 levels in both skin and tumor of the patients
evaluated in the phase I study. It also induced significant
increase in c-peptide levels during fasted period of treatment.
This effect increases over time and with higher dose.
AZD 8055
AZD 8055, is another selective inhibitor of mTORC1
and 2. Dr. Anne Tsao discussed the promising preclinical data
and noted that the first-in-human phase I study is currently
ongoing. A twice a day schedule is being evaluated in a phase
I study for advanced solid tumors. A total of 40 patients will
be enrolled at the MTD with an enriched cohort of patients
with endometrial cancer.
PX-866
Dr. Jimeno discussed the development of PX-866, a
wortmanin analog that inhibits PI3 Kinase. Preclinical studies
have demonstrated that the anticancer activity has been cor-
related with downstream signal inhibition. A monotherapy
phase I study is under evaluation with a daily X5 followed by
2 days off schedule. A total of 18 patients have been enrolled
to date. PX-866 lowers p-S6 ribosomal protein and p-mTOR
in a dose-dependent manner.
It is clear from the above data that evaluation of the
AKT-mTOR axis as a therapeutic target for NSCLC is
moving rapidly into the clinic with encouraging early signs.
Identification of predictive biomarkers and mechanism-based
novel combinations with the new agents will be the next
phase of development of these agents.
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